Supernus Pharmaceuticals (SUPN) Short-term Investments (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Short-term Investments data on file, last reported at $199.4 million in Q1 2026.

• On a quarterly basis, Short-term Investments fell 42.67% year-over-year to $199.4 million in Q1 2026; TTM through Mar 2026 was $199.4 million, a 42.67% decrease from a year earlier, with the FY2025 full-year figure at $180.2 million, down 53.1% from the prior year.
• Short-term Investments for Q1 2026 stood at $199.4 million, up from $180.2 million in the prior quarter.
• Over the last five years, Short-term Investments for SUPN reached as high as $384.3 million in Q4 2024 and fell as low as $105.2 million in Q3 2023.
• Historically, Short-term Investments has averaged $243.2 million across 5 years, with a median of $199.4 million in 2026.
• Across the five-year window, Short-term Investments surged 253.16% in 2024 and tumbled 65.07% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $368.2 million in 2022, then slumped by 51.16% to $179.8 million in 2023, then soared by 113.7% to $384.3 million in 2024, then tumbled by 53.1% to $180.2 million in 2025, then increased by 10.63% to $199.4 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $199.4 million in Q1 2026, $180.2 million in Q4 2025, and $129.8 million in Q3 2025.